MLTX – moonlake immunotherapeutics - class a ordinary shares (US:NASDAQ)
Stock Stats
News
The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock? [Globe and Mail, The (Toronto, Canada)]
MoonLake Immunotherapeutics (MLTX) had its "buy" rating reaffirmed by BTIG Research. They now have a $30.00 price target on the stock.
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting [Yahoo! Finance]
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
MoonLake Immunotherapeutics (MLTX) was upgraded by Wolfe Research from "underperform" to "outperform". They now have a $24.00 price target on the stock.
Form 4 MoonLake Immunotherapeut For: Apr 14 Filed by: Bodenstedt Matthias
Form 4 MoonLake Immunotherapeut For: Apr 10 Filed by: Santos da Silva Jorge
Form 4 MoonLake Immunotherapeut For: Apr 09 Filed by: Bodenstedt Matthias
Form 144 MoonLake Immunotherapeut Filed by: Santos da Silva Jorge
Form 144 MoonLake Immunotherapeut Filed by: Bodenstedt Matthias
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.